Lipid nanoparticles have attracted significant interests in the last two decades, and have
achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the …

The blood-brain barrier (BBB) restricts the access of therapeutic agents to the brain,
complicating the treatment of neurological diseases, such as Alzheimer's disease (AD) …

CNS disorders are on the rise despite advancements in our understanding of their
pathophysiological mechanisms. A major hurdle to the treatment of these disorders is the …

Despite recent advances in cancer therapy, current treatments, including radiotherapy,
chemotherapy, and immunotherapy, although beneficial, present attendant side effects and …

Recent progress in protein-based nanomedicine, inspired by the success of Abraxane®
albumin-paclitaxel nanoparticles, have resulted in novel therapeutics used for treatment of …

Malignant tumor, the leading cause of death worldwide, poses a serious threat to human
health. For decades, natural product has been proven to be an essential source for novel …

Solid lipid nanoparticles (SLNs), the spheroidal-shaped, colloids state lipophilic-natured,
innovative nanoscale particulate materials, are being concurrently prepared by the quality …

This review explores the evolution of lipid‐based nanoparticles (LBNPs) for drug delivery
(DD). Herein, LBNPs are classified into liposomes and cell membrane‐based nanoparticles …

Protein glycosylation is a posttranslational modification that affects more than half of all
known proteins. Glycans covalently bound to biomolecules modulate their functions by both …

Abstract Evaluation of axial properties including preparation, surface functionalization, and
pharmacokinetics for delivery of pharmacologically active molecules and genes lead to …